Added to YB: 2025-10-16
Pitch date: 2025-10-14
ANEB [neutral]
Anebulo Pharmaceuticals, Inc.
-10.55%
current return
Author Info
The Value Road is a deep value investor that's interested in post bankruptcy, NAV, and undervalued micro and nano-cap stocks. I only invest in companies that have layers of value behind them, usually with little or no debt. Sign up for their newsletter.
Company Info
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States.
Market Cap
$93.7M
Pitch Price
$2.56
Price Target
7.40 (+223%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-10.13
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
The 41% Signal: How Strategic Reviews Hint at Hidden Takeovers - Anebulo Pharmaceuticals, Inc.
ANEB (strategic review): ~$90M mkt cap biotech reviewing strategic alternatives including merger, selling lead compound ANEB-001 to pharma partner, or going private. $12M cash, $80M EV. Licensing/sale could double/triple share price; otherwise high dilution risk remains.
Read full article (1 min)